Effect of artemether-lumefantrine policy and improved vector control on malaria burden in KwaZulu-Natal, South Africa

被引:198
作者
Barnes, KI [1 ]
Durrheim, DN
Little, F
Jackson, A
Mehta, U
Allen, E
Dlamini, SS
Tsoka, J
Bredenkamp, B
Mthembu, DJ
White, NJ
Sharp, BL
机构
[1] Univ Cape Town, Div Clin Pharmacol, ZA-7925 Cape Town, South Africa
[2] Hunter New England Populat Hlth, Hlth Protect, Newcastle, NSW, Australia
[3] Univ Cape Town, Dept Stat Sci, ZA-7925 Cape Town, South Africa
[4] MRC, Malaria Lead Res Programme, Durban, South Africa
[5] Mahidol Univ, Fac Trop Med, Bangkok 10700, Thailand
[6] Churchill Hosp, Ctr Vaccinol & Trop Med, Oxford OX3 7LJ, England
基金
英国惠康基金;
关键词
D O I
10.1371/journal.pmed.0020330
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Between 1995 and 2000, KwaZulu-Natal province, South Africa, experienced a marked increase in Plasmodium falciparum malaria, fuelled by pyrethroid and sulfadoxine-pyrimethamine resistance. In response, vector control was strengthened and artemether-lumefantrine (AL) was deployed in the first Ministry of Health artemisinin-based combination treatment policy in Africa. In South Africa, effective vector and parasite control had historically ensured low-intensity malaria transmission. Malaria is diagnosed definitively and treatment is provided free of charge in reasonably accessible public-sector health-care facilities. Methods and Findings We reviewed four years of malaria morbidity and mortality data at four sentinel health-care facilities within KwaZulu-Natal's malaria-endemic area. In the year following improved vector control and implementation of AL treatment, malaria-related admissions and deaths both declined by 89%, and outpatient visits decreased by 85% at the sentinel facilities. By 2003, malaria-related outpatient cases and admissions had fallen by 99%, and malaria-related deaths had decreased by 97%. There was a concomitant marked and sustained decline in notified malaria throughout the province. No serious adverse events were associated causally with AL treatment in an active sentinel pharmacovigilance survey. In a prospective study with 42 d follow up, AL cured 97/98 (99%) and prevented gametocyte developing in all patients. Consistent with the findings of focus group discussions, a household survey found self-reported adherence to the six-dose AL regimen was 96%. Conclusion Together with concurrent strengthening of vector control measures, the antimalarial treatment policy change to AL in KwaZulu-Natal contributed to a marked and sustained decrease in malaria cases, admissions, and deaths, by greatly improving clinical and parasitological cure rates and reducing gametocyte carriage.
引用
收藏
页码:1123 / 1134
页数:12
相关论文
共 49 条
[11]  
Durrheim DN, 1996, S AFR MED J, V86, P1434
[12]   Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice [J].
Farmer, KC .
CLINICAL THERAPEUTICS, 1999, 21 (06) :1074-1090
[13]   Genotyping of Plasmodium falciparum infections by PCR:: a comparative multicentre study [J].
Färnert, A ;
Arez, AP ;
Babiker, HA ;
Beck, HP ;
Benito, A ;
Björkman, A ;
Bruce, MC ;
Conway, DJ ;
Day, KP ;
Henning, L ;
Mercereau-Puijalon, O ;
Ranford-Cartwright, LC ;
Rubio, JM ;
Snounou, G ;
Walliker, D ;
Zwetyenga, J ;
do Rosario, VE .
TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 2001, 95 (02) :225-232
[14]  
FREESE JA, 1994, S AFR J SCI, V90, P417
[15]  
GREENE WH, 1994, EC9410
[16]   HIV infection as a cofactor for severe falciparum malaria in adults living in a region of unstable malaria transmission in South Africa [J].
Grimwade, K ;
French, N ;
Mbatha, DD ;
Zungu, DD ;
Dedicoat, M ;
Gilks, CF .
AIDS, 2004, 18 (03) :547-554
[17]   Anopheles funestus resistant to pyrethroid insecticides in South Africa [J].
Hargreaves, K ;
Koekemoer, LL ;
Brooke, BD ;
Hunt, RH ;
Mthembu, J ;
Coetzee, M .
MEDICAL AND VETERINARY ENTOMOLOGY, 2000, 14 (02) :181-189
[18]   The global distribution and population at risk of malaria: past, present, and future [J].
Hay, SI ;
Guerra, CA ;
Tatem, AJ ;
Noor, AM ;
Snow, RW .
LANCET INFECTIOUS DISEASES, 2004, 4 (06) :327-336
[19]  
*ICH, 2003, E2A
[20]  
Kouznetsov R L, 1977, Trop Doct, V7, P81